Oral safety and efficacy of eucalypt sap resin in the management of recurrent vulvovaginal candidiasis

Exclusion Criteria12

• Participants must be on contraception, and those participants who choose to use hormonal contraception should be on stable levels at least 6 weeks prior to and during the trial
• Ability and willingness to collect vaginal swabs
• Pregnant, planning pregnancy or breastfeeding
• Not willing to use contraception for the duration of the study
• Taking warfarin or any other anti-coagulant medication, diabetic medication, corticosteroids, antibiotics, or immunosuppressive medications/treatments
• Diagnosed with cancer (if active within last five years and excepting skin cancer)
• Individuals diagnosed with significant chronic illness including inflammatory bowel disease, liver disorders, kidney disease, autoimmune disorders, pelvic inflammatory disease, cystitis, sexually transmitted infections (STI), or any other medically diagnosed vulvovaginal conditions (excepting RVVC)
• Treatment of any vaginal infection, STI or urinary tract infection within the last six weeks including the use of vaginal douches, pessaries, probiotics (including vaginal and oral administration) for any reason
• Use of corticosteroids or oral antibiotics for any condition within the last four weeks
• Use of any antifungal treatments regularly for control of RVVC, including medications (i.e., Nystatin or fluconazole) or herbal treatment (i.e., Pau D’arco or horopito). Probiotics are permissible providing the use is regular for four weeks or more and ongoing
• Currently unwell with acute infection or fever or having Covid-19 within the last four weeks
• In poor general health as assessed by Study Investigators